INFLAMMATION, SUBSTANCE USE, SYMPTOMS, AND COGNITION IN PHASE 1 OF THE CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS STUDY

被引：0
|
作者：
Miller, Brian [1 ]
Buckley, Peter [1 ]
McEvoy, Joseph [1 ]
机构：
[1] Augusta Univ, Augusta, GA USA
来源：
SCHIZOPHRENIA BULLETIN | 2017年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
175.3
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [21] Insomnia, Suicidal Ideation, and Suicide Attempts in the Clinical Antipsychotic Trials of Intervention Effectiveness
    Miller, Brian J.
    McEvoy, Joseph P.
    McCall, William, V
    JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (03)
  • [22] Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial
    Schneider, LS
    Ismail, MS
    Dagerman, K
    Davis, S
    Olin, J
    McManus, D
    Pfeiffer, E
    Ryan, JM
    Sultzer, DL
    Tariot, PN
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 57 - 72
  • [23] The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data
    Ozzoude, Miracle
    Nakajima, Shinichiro
    Plitman, Eric
    Chung, Jun Ku
    Kim, Julia
    Iwata, Yusuke
    Caravaggio, Fernando
    Takeuchi, Hiroyoshi
    Uchida, Hiroyuki
    Graff-Guerrero, Ariel
    Gerretsen, Philip
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 89 : 207 - 213
  • [24] Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Kelly, Conor W.
    McEvoy, Joseph P.
    Miller, Brian J.
    SCHIZOPHRENIA RESEARCH, 2019, 209 : 193 - 197
  • [25] Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Swartz, MS
    Perkins, DO
    Stroup, TS
    McEvoy, JP
    Nieri, JM
    Haak, DC
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 33 - 43
  • [26] The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study
    Alisauskiene, Renata
    Loberg, Else-Marie
    Gjestad, Rolf
    Kroken, Rune A.
    Jorgensen, Hugo A.
    Johnsen, Erik
    NORDIC JOURNAL OF PSYCHIATRY, 2019, 73 (4-5) : 281 - 287
  • [27] Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population
    Cascella, Nicola G.
    Kryszak, Debra
    Bhatti, Bushra
    Gregory, Patricia
    Kelly, Deanna L.
    Mc Evoy, Joseph P.
    Fasano, Alessio
    Eaton, William W.
    SCHIZOPHRENIA BULLETIN, 2011, 37 (01) : 94 - 100
  • [28] Correlation Between Violence and Antipsychotic Dosage in Schizophrenia: A Secondary Analysis of The Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Dataset
    Tasmim, Samia
    Kolla, Nathan J.
    Dada, Oluwagbenga
    Bani-Fatemi, Ali
    De Luca, Vincenzo
    PHARMACOPSYCHIATRY, 2019, 52 (05) : 217 - 221
  • [29] Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
    Lieberman, JA
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Rosenheck, RA
    Perkins, DO
    Keefe, RS
    Davis, SM
    Davis, CE
    Lebowitz, B
    Hsiao, J
    Severe, J
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S32 - S32
  • [30] The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
    Meyer, JM
    Nasrallah, HA
    McEvoy, JP
    Goff, DC
    Davis, SM
    Chakos, M
    Patel, JK
    Keefe, RSE
    Stroup, TS
    Lieberman, JA
    SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 9 - 18
12345